BACKGROUND: The elderly population is increasing and more patients in this group undergo Mohs micrographic surgery (MMS). The few publications investigating MMS in elderly people conclude that it is a safe procedure; however, these are single-centre studies without a comparison group. OBJECTIVE: To compare the characteristics of patients, tumours, MMS and 1-year follow-up in patients younger than 80 years, with patients older than 80 years at the time of surgery. METHODS: Data was analysed from REGESMOHS, a prospective cohort study of patients treated with MMS. The participating centres were 19 Spanish hospitals where at least one MMS is performed per week. Data on characteristics of the patient, tumour and surgery were recorded. Follow-up data were collected from two visits; the first within 1 month postsurgery and the second within the first year. RESULTS: From July 2013 to October 2016, 2575 patients that underwent MMS were included in the registry. Of them, 1942 (75.4%) were aged <80 years and 633 (24.6%) were ≥80 years old. In the elderly, the tumour size was significantly higher with a higher proportion of squamous cell carcinoma. Regarding surgery, elderly more commonly had tumours with deeper invasion and required a higher number of Mohs surgery stages, leaving larger defects and requiring more time in the operating room. Despite this, the incidence of postoperative complications was the same in both groups (7%) and there were no significant differences in proportion of relapses in the first-year follow-up. CONCLUSION: The risk of short-term complications and relapses were similar in elderly and younger groups. MMS is a safe procedure in the elderly.
BACKGROUND: The elderly population is increasing and more patients in this group undergo Mohs micrographic surgery (MMS). The few publications investigating MMS in elderly people conclude that it is a safe procedure; however, these are single-centre studies without a comparison group. OBJECTIVE: To compare the characteristics of patients, tumours, MMS and 1-year follow-up in patients younger than 80 years, with patients older than 80 years at the time of surgery. METHODS: Data was analysed from REGESMOHS, a prospective cohort study of patients treated with MMS. The participating centres were 19 Spanish hospitals where at least one MMS is performed per week. Data on characteristics of the patient, tumour and surgery were recorded. Follow-up data were collected from two visits; the first within 1 month postsurgery and the second within the first year. RESULTS: From July 2013 to October 2016, 2575 patients that underwent MMS were included in the registry. Of them, 1942 (75.4%) were aged <80 years and 633 (24.6%) were ≥80 years old. In the elderly, the tumour size was significantly higher with a higher proportion of squamous cell carcinoma. Regarding surgery, elderly more commonly had tumours with deeper invasion and required a higher number of Mohs surgery stages, leaving larger defects and requiring more time in the operating room. Despite this, the incidence of postoperative complications was the same in both groups (7%) and there were no significant differences in proportion of relapses in the first-year follow-up. CONCLUSION: The risk of short-term complications and relapses were similar in elderly and younger groups. MMS is a safe procedure in the elderly.
Authors: Amanda Maisel-Campbell; Katherine A Lin; Sarah A Ibrahim; Bianca Y Kang; Noor Anvery; McKenzie A Dirr; Rachel E Christensen; Juliet L Aylward; Omar Bari; Hamza Bhatti; Diana Bolotin; Basil S Cherpelis; Joel L Cohen; Sean Condon; Sheila Farhang; Bahar Firoz; Algin B Garrett; Roy G Geronemus; Nicholas J Golda; Tatyana R Humphreys; Eva A Hurst; Oren H Jacobson; S Brian Jiang; Pritesh S Karia; Arash Kimyai-Asadi; David J Kouba; James G Lahti; Martha Laurin Council; Marilyn Le; Deborah F MacFarlane; Ian A Maher; Stanley J Miller; Eduardo K Moioli; Meghan Morrow; Julia Neckman; Timothy Pearson; Samuel R Peterson; Christine Poblete-Lopez; Chad L Prather; Jennifer S Ranario; Ashley G Rubin; Chrysalyne D Schmults; Andrew M Swanson; Christopher Urban; Y Gloria Xu; Murad Alam; Simon Yoo; Emily Poon; Vishnu Harikumar; Alexandra Weil; Sanjana Iyengar; Matthew R Schaeffer Journal: JAMA Dermatol Date: 2022-07-01 Impact factor: 11.816
Authors: A J G Leus; M Frie; M S Haisma; J B Terra; B E C Plaat; R J H M Steenbakkers; G B Halmos; E Rácz Journal: J Eur Acad Dermatol Venereol Date: 2020-03-30 Impact factor: 6.166
Authors: C Nätterdahl; J Kappelin; B Persson; K Lundqvist; I Ahnlide; K Saleh; Å Ingvar Journal: J Eur Acad Dermatol Venereol Date: 2022-04-12 Impact factor: 9.228
Authors: Isabella Parente Almeida; Maria Isabel Ramos Saraiva; Maria Cristina de Lorenzo Messina; Luiz Guilherme Martins Castro Journal: An Bras Dermatol Date: 2022-07-15 Impact factor: 2.113